Charming Medical Ltd, a Hong Kong-based wellness services provider rooted in traditional Chinese medicine (TCM), initiated significant corporate governance reforms in July 2026, including abandoning foreign private issuer exemptions on Nasdaq rules and surrendering its dual-class share structure. These moves aim to enhance shareholder protections amid an ongoing trading suspension. Operationally, the company is cautiously scaling its franchise licensing channel and leveraging prepaid wellness service packages to improve revenue visibility. Profitability challenges persist due to fixed lease and staffing costs, while regulatory uncertainties and limited market access remain key concerns.